ARD-101
ARD-101, gut-restricted bitter taste receptor (TAS2R) agonist
Written by Aaron CuhaReviewed Sep 2026
Also known as: TAS2R agonist, Gut-restricted bitter agonist
It reduced hunger in adults by activating bitter taste receptors in the gut, and both of its phase 3 trials in Prader-Willi syndrome were terminated.
Overview
Bitter taste receptors are not confined to the tongue. They line the gastrointestinal tract, where activating them triggers release of gut hormones including GLP-1 and cholecystokinin. ARD-101 was built to exploit that: a molecule designed to stay in the gut, activate those receptors locally, and prompt the body to release its own satiety hormones rather than supplying a drug that mimics them.
That is a genuinely elegant idea, and it is the same design logic that makes linaclotide work: if your target is on the gut lining, you do not need systemic absorption.
It reached the clinic. A published randomised study reports that it reduces hunger in adults. Its most advanced programme was in Prader-Willi syndrome, a genetic disorder whose defining feature is relentless hunger and where no good treatment exists.
Both phase 3 trials in that condition carry status terminated on the registry.
Mechanism of action
An orally administered agonist at type 2 taste receptors, TAS2Rs, engineered to remain within the gastrointestinal lumen rather than being absorbed. TAS2Rs are expressed on enteroendocrine cells throughout the gut, and activating them stimulates secretion of endogenous satiety hormones including glucagon-like peptide-1, cholecystokinin and peptide YY. The strategy is therefore secretagogue rather than agonist: it prompts release of the body's own hormones instead of substituting for them, which in principle preserves physiological regulation and pulsatility that a continuous exogenous agonist overrides.
Human evidence
A published human hunger result and a small completed phase 2, against two terminated phase 3 trials in the lead indication.
- A randomised study reports reduced hunger in adults, which is the mechanism working as designed.
- The weight loss result in the same paper is in diet-induced obese mice and required combination with a DPP-4 inhibitor.
- A phase 2 in adults with obesity enrolled 20 participants and completed.
- The phase 3 in Prader-Willi syndrome enrolled 68 participants and is terminated.
- The open-label extension enrolled 19 and is also terminated.
- No approval anywhere and no published phase 3 result.
What this does not tell you: Reducing hunger and producing weight loss are different endpoints, and this compound has the first in humans and the second only in mice with a second drug added. The human studies are small, 20 participants in the completed phase 2. Two terminated phase 3 trials in the lead indication is a serious fact, and registry status does not give a reason, so this page reports the terminations without asserting why. Prader-Willi syndrome is also a difficult setting in which to succeed, so failure there does not fully settle the mechanism for ordinary obesity.
Reading the research record
ARD-101 is worth recording because the idea deserves to be remembered even though the programme stopped.
Most obesity drugs supply a hormone or mimic one, which overrides the body's own regulation and brings the side effects of continuous receptor occupancy. This attempted something different: stay in the gut, activate receptors that already exist there, and let the body release its own satiety hormones on its own schedule. If that worked it would preserve pulsatility and physiological control in a way an injected agonist cannot.
The human evidence says the mechanism engages. Hunger was reduced in adults. What it has not shown is that reduced hunger translates into weight loss in people, since that half of the result is in mice and needed a second drug.
And the programme's most advanced trials, in a condition defined by uncontrollable hunger where nothing works well, are terminated. Whether that reflects the drug, the indication or something commercial is not in the public record, and this page does not guess.
The evidence, charted
Fig. 1 · evidence composition
4of 4 citations (100%) are in people
Every citation cited here is Human work; no other study type is cited on this page. This count is of our own citation list and understates any literature larger than the sources we cite.
Fig. 2 · evidence over time
Citations here span just two years, 2024 and 2026.
Too few distinct publication years on this page to plot as a timeline.
Fig. 3 · legal status at a glance
US
Not approved
UK
Approved
AU
Not approved
CA
Not approved
Approved in 1 of 4, prescription route in 0, not approved in 3. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Key studies & citations
- Human2026
ARD-101, a gut-restricted TAS2R agonist, reduces hunger in adults and promotes weight loss in DIO mice with DPP-4 inhibition
Reports reduced hunger in adults from a gut-restricted bitter taste receptor agonist, alongside weight loss in diet-induced obese mice when combined with a DPP-4 inhibitor. Note the split: the human result is on hunger, and the weight loss result is in mice and required a second drug.
Molecular Metabolism - Human2024
A study to evaluate ARD-101 in adults with obesity
Phase 2, 20 participants, completed. A small early study, which is the scale most of the human data here comes from.
ClinicalTrials.gov - Human2026
ARD-101 for treatment of Prader-Willi syndrome: the Hunger Elimination or Reduction Objective trial
Phase 3, 68 participants, status TERMINATED. The pivotal trial in the indication the programme was built around.
ClinicalTrials.gov - Human2026
The Hunger Elimination or Reduction Objective open-label extension trial
The open-label extension, 19 participants, status TERMINATED. Both arms of the phase 3 programme ended.
ClinicalTrials.gov
Frequently asked questions
How can a bitter taste receptor make you less hungry?
Because those receptors are not only on your tongue. They line the gut, and activating them makes enteroendocrine cells release the body's own satiety hormones, including GLP-1 and cholecystokinin. The drug is a secretagogue rather than an agonist: it prompts your hormones rather than substituting for them.
Did it cause weight loss?
In people it reduced hunger. The weight loss result in the same publication is in diet-induced obese mice and required adding a DPP-4 inhibitor. Reduced hunger and lost weight are different endpoints, and only the first has been shown in humans.
Why did the phase 3 trials stop?
The registry records both the Prader-Willi phase 3 and its open-label extension as terminated and does not give a reason, so this site does not supply one. It is worth knowing that Prader-Willi syndrome is an unusually hard setting, so a failure there does not by itself settle whether the mechanism works in ordinary obesity.